Mannkind Corp’s Afrezza Diabetes Device Raises Concerns and Idera Pharmaceuticals Announces Positive Phase 2 Trial Results

MannKind Corp. (NASDAQ: MNKD) shares dipped on Friday after a report from FDA staff raised some questions about the company’s diabetes device Afrezza. An FDA committee said it was concerned about certain pharmacology issues that could impact Afrezza’s safety and effectiveness. Concerns included the drug’s potential risks related to bronchospasms and pulmonary function decline in patients with underlying lung disease. The committee also said that available data from studies do not “conclusively support” use in patients with underlying lung disease. The committee issued their report before a